Each year about 5,000 people are diagnosed with ALS. This is such an important conversation. A disease that can weaken a patient's muscles and impact physical function. However, one research company says that could all change soon. Coya Therapeutics has developed a way to isolate a patient problematic T-cells in order to help ultimately slow the decline of not just ALS, but potentially Alzheimer's and other neurodegenerative diseases as well. Founder and Chief Executive Officer at Coya Therapeutics, Dr. Howard Berman, joined Cheddar to discuss more.
